Franklin Genomic AdvancementHELXETF
13F holders, Q1 2024 (March 31)10holders
1famous investor
$32.76avg. 13F price*
At the end of Q1 2024, 10 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings. The largest holders were Glenview Trust Co ($1.1M), Jane Street Group, LLC ($455K) and GTS Securities LLC ($449K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $363K |
| Exits | 2 | $50K |
Ownership 10 holders
| Glenview Trust Co | 0.02% | Reduce -22.8% | 32,625 | $1.1M |
| Jane Street Group, LLC | 0.00% | Reduce -46.2% | 13,886 | $455K |
| GTS Securities LLC | 0.01% | Reduce -72.0% | 13,704 | $449K |
| Citadel Advisors | 0.00% | New | 11,072 | $363K |
| LPL Financial LLC | 0.00% | Add +30.8% | 9,238 | $303K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 7,042 | $231K |
| Susquehanna International Group, LLP | 0.00% | Reduce -7.7% | 6,934 | $227K |
| Osaic Holdings, Inc. | 0.00% | Reduce -25.2% | 297 | $10K |
| Harbour Investments, Inc. | 0.00% | No change | 188 | $6K |
| Citigroup Inc. | 0.00% | New | 15 | $491 |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.